Blackstone Stock: Is Wall Street Bullish or Bearish?

Analysts covering Blackstone (BX) have a 'Moderate Buy' consensus, with a mean price target of $137.29, a 14.6% premium to current share price. UBS maintained a 'Neutral' rating, raising its target to $118.

Original reporting
Published Nov 6, 2026, 6:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Blackstone Stock: Is Wall Street Bullish or Bearish? — source image
Decision brief

The 30-second read

$BXBullishLow
01

Why it matters

The consensus rating and higher price target could attract modest buying interest, but the effect is likely limited without additional catalysts.

02

Market read

Analyst rating update provides modest trading insight for BX; limited broader market relevance.

03

What to watch

No new earnings or deal news; rating change alone may not drive significant price movement.

Relevance 5/10Novelty 4/10Timing: today

Background

Blackstone is a leading alternative investment manager; analyst consensus can influence investor sentiment.

Company-level read

Ticker impact

$BXBullishMedium confidence
Context

Analyst consensus rating for Blackstone (BX) is Moderate Buy with a mean price target of $137.29, up 14.6% from current price.

Expected impact

likely modest upward pressure as investors price in higher target.

Evidence & confidence

Consensus upgrade and higher price target indicate improved outlook, but no new catalyst beyond rating change.

Market effects

May slightly boost perception of the alternative asset management sector.

Limited to US markets where Blackstone trades.

Low global impact.

Counterpoint

Investors may view the consensus as already priced in, limiting upside.

Key entities

  • Blackstone

    Alternative asset manager (ticker BX).

  • UBS

    Provided a neutral rating and raised price target.

Related articles

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.